Reversible mechlorethamine-associated hearing loss in a patient with Hodgkin's disease.
Mechlorethamine, when administered in massive doses (0.6-1.5 mg/kg) to cancer patients in several early studies, caused severe irreversible hearing loss. There have been no reports of ototoxicity with doses of 0.4 mg/kg or less. The authors describe a 36-year-old man who developed profound sensorineural hearing loss during his first cycle of MOPP chemotherapy for Hodgkin's disease. Cyclophosphamide was substituted for mechlorethamine in subsequent cycles and his hearing deficit resolved. This is the first reported case of reversible ototoxicity associated with currently recommended doses of mechlorethamine.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001299:Audiometry; D001309:Auditory Threshold / Q000187:drug effects / Q000502:physiology; D003520:Cyclophosphamide / Q000008:administration & dosage; D003638:Deafness / Q000139:chemically induced* / Q000503:physiopathology; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects*; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone